Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis

References

• National Cancer Institute. Cancer Stat Facts: Hodgkin lymphoma; 2019; [Internet]; [cited 2019 Apr 18]. National Cancer Institute. Available from: https://seer.cancer.gov/statfacts/html/hodg.html
   Google Scholar
• Shah GL, Moskowitz CH. Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood. 2018;131(15):1689–1697.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23):4934–4937.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
   PubMed Web of Science ®Google Scholar
• Bonthapally V, Wu E, Macalalad A, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. Curr Med Res. 2015;31(5):993–1001.
   PubMed Web of Science ®Google Scholar
• Bonthapally V, Yang H, Ayyagar R, et al. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis. Curr Med Res. 2015;31(7):1377–1389.
   PubMed Web of Science ®Google Scholar
• Ladicka M, Sopko L, Chudej J. Real world data on the efficacy and safety of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma in Slovakia. HemaSphere. 2018;2(Suppl. 2):911.
   Google Scholar
• Zagadailov EA, Corman S, Chirikov V, et al. Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. Leuk Lymphoma. 2018;59(6):1413–1419.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane handbook for systematic reviews of interventions. version 6.1 [updated Sep 2020]. Cochrane; 2020. Available from: www.training.cochrane.org/handbook
   Google Scholar
• IOM. Standards for systematic reviews; 2011; [Internet]; [cited 2018 Mar 21]. Institute of Medicine. Available from: https://iom.nationalacademies.org/Reports/2011/Finding-What-Works-in-Health-Care-Standards-for-Systematic-Reviews/Standards.aspx
   Google Scholar
• JBI. Critical appraisal tools; 2018; [Internet]; [cited 2018 Aug 10]. The Joanna Briggs Institute. Available from: joannabriggs.org/research/critical-appraisal-tools.html
   Google Scholar
• Ryan R. Heterogeneity and subgroup analyses in Cochrane Consumers and Communication Group reviews: planning the analysis at protocol stage; 2016; [Internet]; [cited 2019 Jun 28]. Cochrane Consumers and Communication Review Group. Available from: http://cccrg.cochrane.org
   Google Scholar
• EpiGear International; 2020; [Internet]; [cited 2020 Apr 18]. MetaXL version 5.3. Available from: https://www.epigear.com/index_files/metaxl.html
   Google Scholar
• Angelopoulou MK, Vassilakopoulos TP, Batsis I, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. Hematol Oncol. 2018;36(1):174–181.
   PubMed Web of Science ®Google Scholar
• Bazarbachi A, Boumendil A, Finel H, et al. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: a report from the EBMT Lymphoma Working Party. Cancer. 2019;125(1):90–98.
   PubMed Web of Science ®Google Scholar
• Brockelmann PJ, Zagadailov EA, Corman SL, et al. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are ineligible for autologous stem cell transplant: a Germany and United Kingdom retrospective study. Eur J Haematol. 2017;99(6):553–558.
   PubMed Web of Science ®Google Scholar
• Chavda ND, Robinson S, Boumendil A, et al. Outcome of patients with Hodgkin lymphoma treated with brentuximab vedotin for relapse after autologous stem cell transplant: a retrospective analysis of the LWP-EBMT. Blood. 2019;134(Suppl. 1):4018.
   Web of Science ®Google Scholar
• Czyz A, Lojko-Dankowska A, Joks M, et al. Brentuximab vedotin alone and in combination with bendamustine as salvage therapy for primary refractory or relapsed Hodgkin lymphoma: multicentre experience of the Polish Lymphoma Research Group (PLRG). Blood. 2018;132(Suppl. 1):5375.
   Web of Science ®Google Scholar
• Czyz A, Lojko-Dankowska A, Giza A, et al. Improved treatment outcomes for patients with Hodgkin lymphoma relapsing after autologous hematopoietic stem cell transplantation in the brentuximab vedotin era – the real-life report from the Polish Lymphoma Research Group. Blood. 2019;134(Suppl. 1):5276.
   Web of Science ®Google Scholar
• Gandolfi L, Pellegrini C, Casadei B, et al. Long-term responders after brentuximab vedotin: single-center experience on relapsed and refractory Hodgkin lymphoma and anaplastic large cell lymphoma patients. Oncologist. 2016;21(12):1436–1441.
   PubMed Web of Science ®Google Scholar
• Garciaz S, Coso D, Peyrade F, et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Hematol Oncol. 2014;32(4):187–191.
   PubMed Web of Science ®Google Scholar
• Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013;98(4):611–614.
   PubMed Web of Science ®Google Scholar
• Goranova-Marinova VS, Ignatova K, Ganeva P, et al. Prognostic factors influencing outcome after therapy with brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma. Ann Oncol. 2019;30(Suppl. 5):v437–v438.
   Google Scholar
• Ionova T, Afanasiev B, Andrievskih M, et al. Response to brentuximab vedotin and quality of life in patients with relapsed/refractory Hodgkin lymphoma (RR HL) in the real world setting. Blood. 2019;134(Suppl. 1):5296.
   Web of Science ®Google Scholar
• Jansson C, Lagerlof I, Linderoth J, et al. Real life data of brentuximab vedotin use in relapsed/refractory HL in Sweden. HemaSphere. 2018;2(3 Suppl. 3):47–48.
   Google Scholar
• Král Z, Michalka J, Móciková H, et al. Treatment of relapsed/refractory Hodgkin lymphoma: real-world data from the Czech Republic and Slovakia. J Cancer. 2019;10(21):5041–5048.
   PubMed Web of Science ®Google Scholar
• Monjanel H, Deville L, Ram-Wolff C, et al. Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients. Br J Haematol. 2014;166(2):306–308.
   PubMed Web of Science ®Google Scholar
• Pellegrini C, Broccoli A, Pulsoni A, et al. Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. Oncotarget. 2017;8(53):91703–91710.
   PubMedGoogle Scholar
• Perrot A, Monjanel H, Bouabdallah R, et al. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French name patient program experience in 241 patients. Haematologica. 2014;99(Suppl. 1):498.
   Google Scholar
• Piddock K, Atabani S, Gibb A, et al. Real world experience with brentuximab vedotin in relapsed/refractory CD30 positive lymphoma: outcomes in 33 patients after prolonged follow-up at a single UK Centre. Br J Haematol. 2017;176(Suppl. 1):8.
   PubMed Web of Science ®Google Scholar
• Pierdomenico F, Pinto AL, Coutinho J, et al. Limited efficacy of brentuximab vedotin in a heavily pre-treated Hodgkin lymphoma population. Haematologica. 2016;101(Suppl. 5):57.
   PubMed Web of Science ®Google Scholar
• Sarma A, Potter V, Wrench D, et al. Brentuximab vedotin as a bridge to transplant in classical Hodgkin lymphoma: single tertiary centre real-world experience. Br J Haematol. 2016;173(Suppl. 1):108–109.
   Google Scholar
• Tsirigotis P, Vassilakopoulos T, Batsis I, et al. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: a nationwide analysis. Hematol Oncol. 2018;36(4):645–650.
   PubMed Web of Science ®Google Scholar
• Viviani S, Guidetti A, Dalto S, et al. Brentuximab vedotin (BV) an effective treatment for transplant ineligible patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). Haematologica. 2015;100(Suppl. 1):455–456.
   Google Scholar
• Zinzani PL, Pellegrini C, Cantonetti M, et al. Brentuximab vedotin in transplant-naïve relapsed/refractory Hodgkin lymphoma: experience in 30 patients. Oncologist. 2015;20(12):1413–1416.
   PubMed Web of Science ®Google Scholar
• Badar T, Epperla N, Szabo A, et al. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020;4(1):47–54.
   PubMed Web of Science ®Google Scholar
• Houk A, Gopal AK, Libby EN, et al. Prediction of progression-free survival with brentuximab vedotin therapy for relapsed Hodgkin lymphoma: a retrospective analysis. Blood. 2014;124(21):3086.
   Web of Science ®Google Scholar
• Rajeeve S, Shah GL, Moskowitz CH, et al. Survival for relapsed/refractory Hodgkin lymphoma patients with recurrent or persistent disease following autologous hematopoietic stem cell transplantation treated in the modern ERA. Blood. 2018;132(Suppl. 1):2148.
   Web of Science ®Google Scholar
• Svoboda J, Ballard HJ, Bair SM, et al. Current selection patterns, toxicities and outcomes of pre-transplant salvage treatment regimens in patients with relapsed/refractory Hodgkin lymphoma: results of a multicenter retrospective analysis. Blood. 2019;134(Suppl. 1):2855.
   Web of Science ®Google Scholar
• ClinicalTrials: brentuximab vedotin (recombinant) for IV infusion – special drug use surveillance (all-case surveillance). Relapsed or refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphoma; 2020; [Internet]; [cited 2020 Mar 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02139592?term = NCT02139592&draw = 2&rank = 1
   Google Scholar
• Tien FM, Tsai CH, Liu JH, et al. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan. J Formos Med Assoc. 2019;118(10):1466–1470.
   PubMed Web of Science ®Google Scholar
• Jazyltayeva A, Gabbasova S, Kemelbekov N, et al. Preliminary results of using brentuximab vedotin in relapse/refractory Hodgkin's lymphoma. HemaSphere. 2019;3(S1):908.
   Google Scholar
• Karuturi MS, Arai S, Chen RW, et al. Overall survival benefit for patients with relapsed Hodgkin lymphoma treated with brentuximab vedotin after autologous stem cell transplant. Blood. 2012;120(21):3701.
   Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Sasse S, Radford J, et al. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: review of the literature. Crit Rev Oncol Hematol. 2015;95(3):359–369.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Sasse S, Radford J, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: an updated review of published data from the named patient program. Crit Rev Oncol Hematol. 2016;104:65–70.
   PubMed Web of Science ®Google Scholar
• Dada R, Zekri J, Al Saadi R. Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis. Expert Opin Biol Ther. 2016;16(6):739–745.
   PubMed Web of Science ®Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378(4):331–344.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642.
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136–2140.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Schoder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284–292.
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Bociek G, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;126(23):3982.
   Web of Science ®Google Scholar
• Garcia-Sanz R, Sureda A, Alonso-Alvarez S, et al. Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Blood. 2015;126(23):582.
   PubMed Web of Science ®Google Scholar
• Kersten MJ, Driessen J, Zijlstra JM, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Haematologica. 2021;106(4):1129–1137.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP. Relapsed or refractory classical Hodgkin lymphoma: which immunotherapy, and when? Lancet Oncol. 2021;22(4):417–419.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24.
   PubMed Web of Science ®Google Scholar